3'-99mTc-labeling and biodistribution of a CAPL antisense oligodeoxynucleotide

Nuclear Medicine and Biology

Volumn 25, Issue 7, 1998, Pages 651-657

  Hjelstuen, Ole Kristian ^a   Tønnesen, Hanne Hjorth ^a   Bremer, Per Oscar ^b   Verbruggen, Alfons M ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b Isopharma AS   (Norway)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

3' End labeling; CAPL; HPLC; MAG3; Oligonucleotides

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; TECHNETIUM 99M; ANTISENSE OLIGONUCLEOTIDE; MERTIATIDE TC 99M; PERTECHNETIC ACID TC 99M; PROTEIN S 100; RADIOPHARMACEUTICAL AGENT; S100A4 PROTEIN, MOUSE; TECHNETIUM;

ARTICLE; CONJUGATION; DRUG DISTRIBUTION; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; METASTASIS; URINARY EXCRETION; ANIMAL; CHEMISTRY; GENETICS; INJECTION; METABOLISM; MOUSE; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS; MICE; OLIGONUCLEOTIDES, ANTISENSE; RADIOPHARMACEUTICALS; S100 PROTEINS; SODIUM PERTECHNETATE TC 99M; TECHNETIUM; TECHNETIUM TC 99M MERTIATIDE; TISSUE DISTRIBUTION;

EID: 0031662031     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00040-7     Document Type: Article

References (19)

1. Bormans G., Cleynhens B., Adriaens P., Vanbilloen H., De Roo M., Verbruggen A. Investigation of the labelling characteristics of Tc-99m-mercaptoacetyltriglycine. . Nucl. Med. Biol. 22:1995;229-349.
2. Davies B.R., Davies M.P., Gibbs F.E., Barraclough R., Rudland P.S. Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium binding protein, but not with the oncogene EJ-ras-1. Oncogene. 8:1993;999-1008.
3. 2+-binding protein family. Genes Rev. 3:1989;1086-1093.
4. Engelkamp D., Schäfer B.W., Mattei M.G., Erne P., Heizmann C.W. Six S100 genes are clustered on human chromosome 1q21 Identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E . . Proc. Natl. Acad. Sci. USA. 90:1993;6547-6551.
5. Herold M. and Hummel M. (1991) Purification of synthetic oligonucleotides by HPLC. Application Note, Hewlett-Packard. 6, 1-4. Publication number 12-5091-1466E.
6. Hnatowich D.J., Winnard P. Jr, Virzi F., Fogarasi M., Sano T., Smith C.L., Cantor C.R., Rusckowski M. Technetium-99m labeling of DNA oligonucleotides. J. Nucl. Med. 36:1995;2306-2314.
7. Milligan J.F., Matteucci M.D., Martin J.C. Current concepts in antisense drug design. J. Med. Chem. 36:1993;1923-1937.
8. Milligan J.F., Jones R.J., Froehler B.C., Matteucci M.D. Development of antisense therapeutics. NY Acad. Sci. Ann. 716:1994;228-241.
9. Mælandsmo G.M., Hovig E., Skrede M., Engebraaten O., Flørenes V.A., Myklebost O., Grigorian M., Lukanidin E., Scanlon K.J., Fodstad Ø. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res. 56:1996;5490-5498.
10. 2+-binding proteins of the S100 family in malignant human breast-cancer cell lines and biopsy samples. Int. J. Cancer. 57:1994;684-690.
11. Rojanasakul Y. Antisense oligonucleotide therapeutics Drug delivery and targeting . Advanced Drug Deliv. Rev. 18:1996;115-131.
12. Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally H-3-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Molec. Pharmacol. 45:1994;932-943.
13. Schneider R.F., Subramanian G., Feld T.A., et al. N,N′-bis(S-benzoylmercaptoacetamido)ethylenediamine and propylenediamine ligands as renal function imaging agents. I. Alternate synthetic methods. J. Nucl. Med. 25:1984;223-229.
14. Shaw J.-P., Kent K., Bird J., Fishback J., Froehler B. Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucl. Acids Res. 19:1991;747-750.
15. Stein C.A., Cheng Y.C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science. 260:1993;1004-1012.
16. Uhlmann E., Peyman A. Antisense oligonucleotides A new therapeutic principle . Chem. Rev. 90:1990;544-584.
17. Verbeke K., Hjelstuen O., Debrock E., Cleynhens B., De Roo M., Verbruggen A. Comparative evaluation of Tc-99m-Hynic-HSA and Tc-99m-MAG3-HSA as possible blood pool agents. Nucl. Med. Comm. 16:1995;942-957.
18. Visser G.W.M., Gerretsen M., Herscheid J.D.M., et al. Labelling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer A technical protocol . J. Nucl. Med. 34:1993;1953-1963.
19. Wagner R.W., Matteucci M.D., Lewis J.G., Gutierrez A.J., Moulds C., Froehler B.C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 260:1993;1510-1513.